Cochrane · systematic review · CD001191

Rivastigmine for Alzheimer's disease

Birks, JS, Chong, LY, Grimley Evans, J · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library

Dementia and Cognitive Improvement2 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 8 · 100%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Rivastigmine compared to placebo for Alzheimer's disease

Population: patients with Alzheimer's disease, mild to moderate

CD001191.PUB4 (current) · 8 questions

Outcome	Effect	Evidence	Status / GRADE
Cognitive function (change from baseline at 26 weeks using ADAS‐Cog) Rivastigmine vs placebo	no estimate extracted	6 studies · 3232 participants	Moderate
Cognitive function (change from baseline at 26 weeks using MMSE) Rivastigmine vs placebo	no estimate extracted	6 studies · 3205 participants	Moderate
Activities of daily living (change from baseline at 26 weeks measured using various scales) Rivastigmine vs placebo	no estimate extracted	6 studies · 3230 participants	Moderate
Physician rated global impression tests (no change or worse compared with baseline, measured using Global Impression of Change at 26 weeks) Rivastigmine vs placebo	OR 0.68 [0.58, 0.8]	7 studies · 3338 participants	Moderate
Behavioural symptoms (change from baseline at 26 weeks measured using various scales) Rivastigmine vs placebo	no estimate extracted	3 studies · 1529 participants	Moderate
Acceptability of treatment (as measured by withdrawals from trials before end of treatment at 26 weeks) Rivastigmine vs placebo	OR 2.01 [1.71, 2.37]	7 studies · 3569 participants	Moderate
Incidence of adverse events (at least one adverse event by 26 weeks) Rivastigmine vs placebo	OR 2.14 [1.8, 2.53]	7 studies · 3587 participants	Moderate
Quality of life of patients or carers (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) Rivastigmine vs placebo	no estimate extracted	1 study · 529 participants	Moderate

Rivastigmine compared to placebo for Alzheimer's disease

Population: patients with Alzheimer's disease, mild to moderate

CD001191.PUB3 · 8 questions

Outcome	Effect	Evidence	Status / GRADE
Cognitive function (change from baseline at 26 weeks using ADAS‐Cog) Rivastigmine vs placebo	no estimate extracted	6 studies · 3232 participants	Moderate
Cognitive function (change from baseline at 26 weeks using MMSE) Rivastigmine vs placebo	no estimate extracted	6 studies · 3205 participants	Moderate
Activities of daily living (change from baseline at 26 weeks measured using various scales) Rivastigmine vs placebo	no estimate extracted	6 studies · 3230 participants	Moderate
Physician rated global impression tests (no change or worse compared with baseline, measured using Global Impression of Change at 26 weeks) Rivastigmine vs placebo	OR 0.68 [0.58, 0.8]	7 studies · 3338 participants	Moderate
Behavioural symptoms (change from baseline at 26 weeks measured using various scales) Rivastigmine vs placebo	no estimate extracted	3 studies · 1529 participants	Moderate
Acceptability of treatment (as measured by withdrawals from trials before end of treatment at 26 weeks) Rivastigmine vs placebo	OR 2.01 [1.71, 2.37]	7 studies · 3569 participants	Moderate
Incidence of adverse events (at least one adverse event by 26 weeks) Rivastigmine vs placebo	OR 2.14 [1.8, 2.53]	7 studies · 3587 participants	Moderate
Quality of life of patients or carers (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) Rivastigmine vs placebo	no estimate extracted	1 study · 529 participants	Moderate